Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Shepherd, S.T., Litchfield, K. & Turajlic, S. (2019). Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma. Annals of oncology, Vol.30 (3), pp. 355-357.

Turajlic, S. (2019). Standing on the shoulders of giants. Nature medicine, Vol.25 (3), pp. 357-357.

Spain, L., Tippu, Z., Larkin, J.M., Carr, A. & Turajlic, S. (2019). How we treat neurological toxicity from immune checkpoint inhibitors. Esmo open, Vol.4 (Suppl 4), pp. e000540-e000540.  show abstract

Amaria, R.N., Menzies, A.M., Burton, E.M., Scolyer, R.A., Tetzlaff, M.T., Antdbacka, R., Ariyan, C., Bassett, R., Carter, B., Daud, A., et al. (2019). Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The lancet oncology, Vol.20 (7), pp. e378-e389.

Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. (2019). Resolving genetic heterogeneity in cancer. Nature reviews genetics, Vol.20 (7), pp. 404-416.

Flynn, M., Pickering, L., Larkin, J. & Turajlic, S. (2018). Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic advances in medical oncology, Vol.10, pp. 175883591877742-175883591877742.

Turajlic, S., Swanton, C. & Boshoff, C. (2018). Kidney cancer: The next decade. The journal of experimental medicine, Vol.215 (10), pp. 2477-2479.  show abstract

Lim, K.H., Spain, L., Barker, C., Georgiou, A., Walls, G., Gore, M., Turajlic, S., Board, R., Larkin, J.M. & Lorigan, P., et al. (2018). Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. Esmo open, Vol.3 (2), pp. e000317-e000317.

Abbosh, C., Birkbak, N.J., Wilson, G.A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D.A., Veeriah, S., Rosenthal, R., et al. (2018). Erratum: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, Vol.554 (7691), pp. 264-264.

Arce Vargas, F., Furness, A.J., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M.H., Ruef, N., Roddie, C., et al. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer cell, Vol.33 (4), pp. 649-663.e4.

Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Horswell, S., Chambers, T., O’Brien, T., Lopez, J.I., Watkins, T.B., Nicol, D., et al. (2018). Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, Vol.173 (3), pp. 595-610.e11.

Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J.I., Nicol, D., O’Brien, T., Larkin, J., Horswell, S., et al. (2018). Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, Vol.173 (3), pp. 581-594.e12.

Mitchell, T.J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J.H., O’Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L.R., et al. (2018). Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, Vol.173 (3), pp. 611-623.e17.

Tio, M., Rai, R., Ezeoke, O.M., McQuade, J.L., Zimmer, L., Khoo, C., Park, J.J., Spain, L., Turajlic, S., Ardolino, L., et al. (2018). Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European journal of cancer, Vol.104, pp. 137-144.

Turajlic, S. & Larkin, J. (2018). Immunotherapy for Melanoma Metastatic to the Brain. New england journal of medicine, Vol.379 (8), pp. 789-790.

Spain, L., Walls, G., Messiou, C., Turajlic, S., Gore, M. & Larkin, J. (2017). Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer immunology, immunotherapy, Vol.66 (1), pp. 113-117.

Arce Vargas, F., Furness, A.J., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M.H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, Vol.46 (4), pp. 577-586.

Abbosh, C., Birkbak, N.J., Wilson, G.A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D.A., Veeriah, S., Rosenthal, R., et al. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, Vol.545 (7655), pp. 446-451.

Jamal-Hanjani, M., Wilson, G.A., McGranahan, N., Birkbak, N.J., Watkins, T.B., Veeriah, S., Shafi, S., Johnson, D.H., Mitter, R., Rosenthal, R., et al. (2017). Tracking the Evolution of Non–Small-Cell Lung Cancer. New england journal of medicine, Vol.376 (22), pp. 2109-2121.

Turajlic, S. & Swanton, C. (2017). Implications of cancer evolution for drug development. Nature reviews drug discovery, Vol.16 (7), pp. 441-442.

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J.L., Wong, Y.N., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017). Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. The lancet oncology, Vol.18 (8), pp. 1009-1021.

Litchfield, K., Turajlic, S. & Swanton, C. (2017). The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. Cancer discovery, Vol.7 (8), pp. 796-798.

(2017). TRACERx Renal: tracking renal cancer evolution through therapy. Nature reviews urology, Vol.14 (10), pp. 575-576.

McGranahan, N., Rosenthal, R., Hiley, C.T., Rowan, A.J., Watkins, T.B., Wilson, G.A., Birkbak, N.J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017). Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, Vol.171 (6), pp. 1259-1271.e11.

Spain, L., Higgins, R., Gopalakrishnan, K., Turajlic, S., Gore, M. & Larkin, J. (2016). Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Annals of oncology, Vol.27 (6), pp. 1135-1137.

Turajlic, S. & Swanton, C. (2016). Metastasis as an evolutionary process. Science, Vol.352 (6282), pp. 169-175.

Turajlic, S. & Larkin, J. (2016). Systemic treatment of advanced papillary renal cell carcinoma: Where next?. European journal of cancer, Vol.69, pp. 223-225.

Joshi, K., Furness, A.J., Oakes, T., Heather, J., Spain, L.A., Wong, Y.N., Ben Aissa, A., Stares, M., Smith, M.J., Strauss, D.C., et al. (2016). Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM). Journal of clinical oncology, Vol.34 (15_suppl), pp. TPS9599-TPS9599.

Spain, L., Walls, G., Julve, M., O'Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J. & Larkin, J., et al. (2016). Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann oncol, .

Turajlic, S., McGranahan, N. & Swanton, C. (2015). Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica et biophysica acta (bba) - reviews on cancer, Vol.1855 (2), pp. 264-275.

Gulati, S., Turajlic, S., Larkin, J., Bates, P.A. & Swanton, C. (2015). Relapse models for clear cell renal carcinoma. The lancet oncology, Vol.16 (8), pp. e376-e378.

Soultati, A., Stares, M., Swanton, C., Larkin, J. & Turajlic, S. (2015). How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Current opinion in urology, Vol.25 (5), pp. 358-366.

Turajlic, S., Larkin, J. & Swanton, C. (2015). Academically led clinical trials: challenges and opportunities: Figure 1. Annals of oncology, Vol.26 (10), pp. 2010-2011.

Turajlic, S. & Swanton, C. (2015). Tracking tumour evolution through liquid biopsy. Nature reviews clinical oncology, Vol.12 (10), pp. 565-566.

Turajlic, S., Larkin, J. & Swanton, C. (2015). SnapShot: Renal Cell Carcinoma. Cell, Vol.163 (6), pp. 1556-1556.e1.

Turajlic, S., Furney, S.J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C., Hayes, A., Gore, M., et al. (2014). Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Annals of oncology, Vol.25 (5), pp. 959-967.

Furney, S.J., Turajlic, S., Stamp, G., Thomas, J.M., Hayes, A., Strauss, D., Gavrielides, M., Xing, W., Gore, M., Larkin, J., et al. (2014). The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment cell & melanoma research, Vol.27 (5), pp. 835-838.

Sanchez-Laorden, B., Viros, A., Girotti, M.R., Pedersen, M., Saturno, G., Zambon, A., Niculescu-Duvaz, D., Turajlic, S., Hayes, A., Gore, M., et al. (2014). BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. Science signaling, Vol.7 (318), pp. ra30-ra30.

Furney, S.J., Pedersen, M., Gentien, D., Dumont, A.G., Rapinat, A., Desjardins, L., Turajlic, S., Piperno-Neumann, S., de la Grange, P., Roman-Roman, S., et al. (2013). SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma. Cancer discovery, Vol.3 (10), pp. 1122-1129.

Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013). Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. Cancer discovery, Vol.3 (2), pp. 158-167.

Khattak, M., Fisher, R., Turajlic, S. & Larkin, J. (2013). Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Therapeutic advances in medical oncology, Vol.5 (2), pp. 105-118.

Furney, S.J., Turajlic, S., Stamp, G., Nohadani, M., Carlisle, A., Thomas, J.M., Hayes, A., Strauss, D., Gore, M., van den Oord, J., et al. (2013). Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. The journal of pathology, Vol.230 (3), pp. 261-269.

Turajlic, S., Ali, Z., Yousaf, N. & Larkin, J. (2013). Phase I/II RAF kinase inhibitors in cancer therapy. Expert opinion on investigational drugs, Vol.22 (6), pp. 739-749.

Turajlic, S., Furney, S.J., Lambros, M.B., Mitsopoulos, C., Kozarewa, I., Geyer, F.C., MacKay, A., Hakas, J., Zvelebil, M., Lord, C.J., et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome research, Vol.22 (2), pp. 196-207.

Natrajan, R., Mackay, A., Lambros, M.B., Weigelt, B., Wilkerson, P.M., Manie, E., Grigoriadis, A., A'Hern, R., van der Groep, P., Kozarewa, I., et al. (2012). A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. The journal of pathology, Vol.227 (1), pp. 29-41.

Furney, S.J., Turajlic, S., Fenwick, K., Lambros, M.B., MacKay, A., Ricken, G., Mitsopoulos, C., Kozarewa, I., Hakas, J., Zvelebil, M., et al. (2012). Genomic characterisation of acral melanoma cell lines. Pigment cell & melanoma research, Vol.25 (4), pp. 488-492.

Larkin, J.M., Turajlic, S., Nathan, P.D., Lorigan, P., Stamp, G., Gonzalez de Castro, D., Martin, N., Griffiths, J., Edmonds, K., Sarker, S., et al. (2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). J clin oncol, Vol.29 (15_suppl), p. TPS229.  show abstract

Perez, A., Turajlic, S., Szyszko, T., O'Doherty, M., Calonje, E., Harries, M. & Acland, K. (2010). Generalized melanosis and melanuria in a patient with metastatic melanoma. Clinical and experimental dermatology, Vol.35 (3), pp. e37-e39.

Spain, L., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J. & Larkin, J., et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Annals of oncology, , pp. mdw558-mdw558.

O’Reilly, A., Hughes, P., Mann, J., Lai, Z., Teh, J.J., Mclean, E., Edmonds, K., Lingard, K., Chauhan, D., Lynch, J., et al. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive care in cancer, .

Ferronika, P., Hof, J., Kats-Ugurlu, G., Sijmons, R.H., Terpstra, M.M., de Lange, K., Leliveld-Kors, A., Westers, H. & Kok, K. Comprehensive Profiling of Primary and Metastatic ccRCC Reveals a High Homology of the Metastases to a Subregion of the Primary Tumour. Cancers, Vol.11 (6), pp. 812-812.  show abstract


Conferences

Turajlic, S. (2017). TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx)), JOURNAL OF PATHOLOGY, Vol.241, p.S3.

Oudard, S., Mejean, A., Topart, D., Thuret, R., Tournigand, C., Salomon, L., Thiery-Vuillemin, A., Guichard, G., Le Moulec, S., Houlgatte, A., et al. (2017). Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium), ANNALS OF ONCOLOGY, Vol.28.

Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013). Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Presented at Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC, Experimental and Molecular Therapeutics, .

Larkin, J.M., Turajlic, S., Nathan, P.D., Lorigan, P., Stamp, G., Gonzalez de Castro, D., Martin, N., Griffiths, J., Edmonds, K., Sarker, S., et al. (2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM)., Journal of Clinical Oncology, Vol.29 (15_suppl), p.TPS229.

In this section

Research overview Research projects Publications